MeCP2 is a methyl DNA-binding transcriptional regulator that contributes to the development and function of CNS synapses; however, the requirement for MeCP2 in stimulus-regulated behavioral plasticity is not fully understood. Here we show that acute viral manipulation of MeCP2 expression in the nucleus accumbens (NAc) bidirectionally modulates amphetamine (AMPH)induced conditioned place preference. Mecp2 hypomorphic mutant mice have more NAc GABAergic synapses and show deficient AMPH-induced structural plasticity of NAc dendritic spines. Furthermore, these mice show deficient plasticity of striatal immediate early gene inducibility after repeated AMPH administration. Notably, psychostimulants induce phosphorylation of MeCP2 at Ser421, a site that regulates MeCP2's function as a repressor. Phosphorylation is selectively induced in GABAergic interneurons of the NAc, and its extent strongly predicts the degree of behavioral sensitization. These data reveal new roles for MeCP2 both in mesolimbocortical circuit development and in the regulation of psychostimulant-induced behaviors.
a r t I C l e S Drugs of abuse drive changes in behavior by altering the function and plasticity of reward-related circuits in the brain 1 . The mesolimbocortical dopamine circuit is comprised of dopaminergic neurons in the ventral tegmental area (VTA) and their synaptic targets in the NAc, frontal cortex and associated limbic structures. Repeated psychostimulant exposure produces changes in both functional and structural plasticity of synapses in the striatum [2] [3] [4] , and these alterations are thought to contribute to the expression of behavioral sensitization and conditioned place preference (CPP). Considerable evidence suggests that this process depends on the regulated transcription of new gene products 5, 6 . Psychostimulant-activated signaling pathways converge in the NAc to regulate the activity and/or expression of several transcriptional regulators (for example, ΔFosB, MEF2 and NF-κB) that subsequently modulate synapses [6] [7] [8] [9] [10] .
Loss-of-function mutations in the methyl DNA-binding transcriptional regulator methyl CpG-binding protein-2 (MeCP2) cause the neurodevelopmental disorder Rett syndrome (RTT) 11 . The onset of RTT symptoms coincides with the time during postnatal development when sensory-driven neuronal activity is required for refinement of cortical circuitry, suggesting that RTT may have a synaptic pathophysiology 11 . A variety of developmental synaptic abnormalities have been detected in Mecp2 null mice, including decreases in the number of hippocampal glutamatergic synapses 12 , shifts in the balance between excitatory and inhibitory synaptic transmission in somatosensory cortex 13 and an extended period of visual cortical plasticity 14 . However, evidence suggests that MeCP2 also contributes to the function and plasticity of mature neurons. For example, Cre-mediated recombination of a conditional Mecp2 allele in cultured neurons after synaptogenesis induces an acute decrease in frequency of miniature excitatory postsynaptic currents that mimics the effects of the Mecp2 null mutation 15 . Furthermore, conditional re-expression of MeCP2 in Mecp2 null neurons after birth substantially delays neurological symptoms and prolongs lifespan, suggesting that these phenotypes arise at least in part from the lack of MeCP2 expression in mature neurons 16 . Hypomorphic mutations in Mecp2 are associated with limited motor phenotypes 17, 18 , thereby rendering mice bearing them suitable for broader behavioral analyses. Previous studies have demonstrated that mutant alleles of Mecp2 are associated with changes in anxiety, altered social interactions and certain impairments in learning and memory [17] [18] [19] [20] [21] . However, the mechanisms by which MeCP2 influences these behaviors, and whether they arise as a result of developmental abnormalities or functions of MeCP2 in the mature brain, have remained largely unexplored.
MeCP2 is rapidly phosphorylated at Ser421 (pMeCP2) in response to synaptic activity, suggesting a stimulus-dependent mechanism of MeCP2 regulation 22 . In the absence of synaptic activity, MeCP2 binds to and is required for repression of promoter IV in the gene encoding brain-derived neurotrophic factor (BDNF), an activity-inducible secreted protein that exerts many effects on synaptic function 23, 24 . Overexpression of a nonphosphorylatable S421A mutant MeCP2 inhibits activity-dependent expression of Bdnf exon IV, indicating that phosphorylation at this site is required for dynamic derepression of Bdnf 22 . These data are of significance because they demonstrate that Ser421 phosphorylation modulates the ability of MeCP2 to act as a transcriptional repressor, suggesting that this phosphorylation event can be used as a surrogate measure of changes in the functional state of MeCP2-dependent transcriptional pathways in vivo.
Here we have investigated whether MeCP2 may contribute to psychostimulant-regulated behaviors. We found that acute viralmediated knockdown of MeCP2 in adult NAc enhanced AMPHinduced CPP, whereas MeCP2 overexpression reduced CPP, suggesting that MeCP2 acts to limit the rewarding properties of psychostimulants. In a strain of mice bearing a hypomorphic mutation in Mecp2, we found altered behavioral responses to acute and repeated AMPH treatment and we identified changes in both the development and plasticity of striatal synapses. Finally, we show that psychostimulants lead to rapid, dopamine-dependent phosphorylation of MeCP2 in NAc GABAergic interneurons. Together, these data define new roles for MeCP2 in the development and function of the mesolimbocortical dopamine circuit, and they raise the possibility that AMPH-induced alterations in striatal GABAergic interneuron function may contribute to behavioral adaptations to psychostimulants.
RESULTS

MeCP2 modulates AMPH-induced behaviors
To determine whether MeCP2 in adult brain is required for AMPHinduced behaviors, we injected lentivirus into the NAc to induce shRNA-mediated knockdown or overexpression of MeCP2 in C57BL6/J mice ( Fig. 1 and Supplementary Fig. 1 ). Compared with those in mice expressing a control scrambled shRNA (SCR), locomotor activities in mice expressing the shRNA against MeCP2 were significantly enhanced after acute administration of 3 mg AMPH per kilogram body weight ( Fig. 1e and Supplementary Fig. 1b ).
Repeated AMPH injection over 5 consecutive days drove a progressive increase in locomotor activity in both SCR-and MeCP2 shRNA-expressing mice. However, on each day, the locomotor activities of the MeCP2 shRNA-expressing mice were greater than those of controls ( Fig. 1e) . In AMPH-induced CPP, control SCR-infected mice showed dose dependence, preferring the chamber paired with 3 mg kg −1 but not with 1 mg kg −1 AMPH (Fig. 1f) . By contrast, MeCP2 shRNA-expressing mice showed a significant preference for the AMPH-paired chamber at both doses, suggesting that reducing expression of MeCP2 in the NAc increases the rewarding properties of AMPH ( Fig. 1e) . Consistent with this interpretation, overexpression of MeCP2 in the NAc (Fig. 1g-j ) eliminated preference for the 3 mg kg −1 AMPH-paired chamber (Fig. 1k) . Collectively, these data suggest that MeCP2 in the NAc may function to limit the rewarding properties of AMPH.
We next examined locomotor responses to AMPH in mice bearing a hypomorphic mutation in Mecp2 (Mecp2 308 ) 17 . These mice express a C-terminally truncated form of MeCP2 and show a mild version of the neurological phenotypes observed in Mecp2 null mice 25 . In the open field, there were no significant differences in baseline locomotor activities between the Mecp2 308/y mutant (hereafter referred to as MUT) mice and their Mecp2 +/y wild-type (hereafter referred to as WT) littermates ( Fig. 2a ). Both MUT and WT mice had enhanced locomotor activities after acute AMPH administration; however, the MUT mice responded more robustly than WT mice to 2 and 3 mg kg −1 AMPH ( Fig. 2a) . Repeated daily injection of 2 mg kg −1 AMPH over 5 consecutive days drove a progressive increase in locomotion in the WT mice. However, no significant enhancement was detected in MUT mice over the same period ( Fig. 2b) . MUT Open arrowheads indicate absence of MeCP2 expression in GFP-expressing cells. (e) Open field locomotor activity after daily administration of AMPH in C57BL/6 mice expressing an shRNA targeting MeCP2 (n = 12) or a control scrambled shRNA in the NAc (SCR, n = 14). Repeated-measures analysis of variance (ANOVA) showed a significant effect of treatment (F 1,24 = 8.95, P = 0.006) and days (F 4,96 = 23.4, P < 0.0001). *P < 0.05, pairwise comparisons between groups. (f) CPP ratios after pairing with one of two AMPH doses in C57BL/6 mice expressing an shRNA targeting MeCP2 or a control SCR shRNA in the NAc (n = 7 or 8 per group). ANOVA revealed a significant dose-by-treatment interaction (F 1,28 = 5.6, P = 0.026; *P = 0.018, shRNA-MeCP2 compared to shRNA-SCR at 1 mg kg −1 AMPH). VOLUME 13 | NUMBER 9 | SEPTEMBER 2010 nature neurOSCIenCe a r t I C l e S mice also did not show enhanced locomotion after repeated AMPH administration when mice were injected with 3 mg kg −1 AMPH for 5 consecutive days in their home cages and then challenged with AMPH or vehicle in the open field after a 7-d period of withdrawal ( Supplementary Fig. 2 ). It is possible that the elevated acute locomotor activity in the MUT mice precludes further enhancement upon repeated AMPH administration. However, locomotor activity of MUT mice after acute administration of 3 mg kg −1 AMPH ( Fig. 2a ) was significantly greater than activity after repeated exposure to 2 mg kg −1 AMPH ( Fig. 2b) , raising the alternative possibility that mechanisms of locomotor sensitization may be impaired by the Mecp2 308 mutation. Of importance, although local viral knockdown of Mecp2 in the NAc phenocopied the enhanced locomotor response to acute AMPH seen in the MUT mice, the virally injected mice showed normal locomotor sensitization to repeated AMPH injection ( Fig. 1e) .
As the Mecp2 308 mutation is constitutive, differences between these data sets raise the possibility that MeCP2 may contribute to psychostimulant-regulated behaviors not only through its actions in the adult NAc but also through its actions during development and/or in other adult brain regions. Finally, to determine whether the Mecp2 308 mutation affects the rewarding properties of AMPH, we tested WT and MUT mice in CPP. WT mice showed a dose-dependent increase in CPP, significantly preferring a chamber paired with 3 mg kg −1 AMPH but not with 1 mg kg −1 AMPH (Fig. 2c) . By contrast, MUT mice showed no significant preference for the drug-paired chamber at either dose. Their lack of CPP could arise either from impaired reward processing or from contextual learning deficits. As a learning-independent measure of reward, we assessed sucrose preference in the Mecp2 308 mice. Both WT and MUT mice showed a dose-dependent preference for sucrose over water ( Fig. 2d) . However, MUT mice had a significantly lower preference for sucrose than WT mice at low sucrose concentrations. By contrast, WT and MUT mice showed similar responses to a series of quinine concentrations. Although sucrose preference is an indirect measure of reward valuation, it does not permit us to exclude the possibility that contextual learning deficits may contribute to impaired CPP in the Mecp2 308/y mice. Nonetheless, both the sucrose preference and CPP results suggest that the Mecp2 308 mutation impairs reward processing, whereas local knockdown of Mecp2 in the NAc of adult mice enhances reward. Results from both experiments indicate that MeCP2 makes important functional contributions to reward-related behaviors. However, like the sensitization data above, they raise the possibility that MeCP2 may differentially control these behaviors through its actions at different times in development and/or in different regions of the brain.
Altered NAc synapses in Mecp2 mutant mice
Synaptic connections in the NAc represent a target of psychostimulantinduced plasticity 26, 27 . To determine whether synapses in the NAc are affected by the Mecp2 308 mutation, we immunostained coronal brain sections through the NAc of Mecp2 +/y WT and Mecp2 308/y MUT mice with antibodies to presynaptic markers for both GABAergic (VGAT, GAD65) and glutamatergic (VGLUT1) synapses ( Fig. 3) . We observed a significant increase in the overall intensities of VGAT and GAD65 immunoreactivities in the NAc of MUT compared with WT mice and a similar increase in numbers of VGAT-or GAD65-positive puncta ( Fig. 3a,b,d ,e,g,h,j,k). No differences between WT and MUT mice were detected in the intensities of VGLUT1 staining or in the numbers of VGLUT1-positive puncta ( Fig. 3c,f,i,l) . These data show that MeCP2 is important for establishing the number of GABAergic synapses in the NAc, which may subsequently affect behavioral responses to psychostimulants.
Repeated treatment with AMPH increases the density of dendritic spines on medium spiny neurons (MSNs) in the NAc 2 . These spines are sites of cortical glutamatergic synaptic contacts, and long-lasting changes in spine numbers are hypothesized to contribute to persistent behavioral adaptations after chronic psychostimulant treatment 7,9 . To determine whether the Mecp2 308 mutation affects this structural plasticity, we treated WT or MUT mice with vehicle or with 3 mg kg −1 AMPH for 21 consecutive days and then processed the brains for Golgi-Cox staining ( Fig. 4) . There were no differences between the dendritic spine densities of vehicle-treated WT and MUT mice ( Fig. 4b) , 25 F 7,53 = 20.0, P < 0.001; *P < 0.001, WT compared to MUT for 3 mg kg −1 ; # P = 0.019, WT compared to MUT for 2 mg kg −1 . (b) Open field locomotor activity induced by repeated 2 mg kg −1 AMPH. By repeated-measures analysis of variance (RMANOVA), the within-subject effect of days and the day by genotype interaction were not significant. However, the betweensubjects effect of genotype was significant (F 1, 14 = 15.0, P < 0.002; *P < 0.05, MUT compared to WT). By RMANOVA within each genotype, the days effect was significant for WT (F 4,28 = 5.12, P < 0.003), but not for MUT (F 4,28 = 0.609; P = 0.659). (c) CPP in MUT and WT mice (n = 9 per genotype for 1 mg kg −1 ; n = 12 per genotype for 3 mg kg −1 ). For WT, RMANOVA found a significant preference for the AMPH-paired chamber at 3 mg kg −1 (chamber-by-dose, F 1,18 = 4.29, P = 0.05); *P < 0.001, vehicle-paired compared to AMPH-paired chamber). In MUT, there was no significant main effect of dose (F 1,20 = 1.45, P = 0.24) or chamber preference (F 1,20 = 1.05, P = 0,32) and the chamber by dose interaction was not significant (F 1,20 = 0.50, P = 0.49). (d) Sucrose preference in WT and MUT littermates (n = 9 mice per group). For sucrose, RMANOVA showed significant main effects of concentration (F 3,48 = 19.8, P < 0.0001) and genotype (F 1,16 = 12.9, P = 0.002), and a significant concentration by genotype interaction (F 3,14 = 2.78, P = 0.051). *P < 0.05, WT compared to MUT at 0.25% and 0.5%. P = 0.079, WT compared to MUT at 1.0%. For quinine, RMANOVA revealed a main effect of concentration (F 2,34 = 12.5, P = 0.001), but no genotype effect. Results displayed as mean ± s.e.m.
a r t I C l e S which is consistent with our VGLUT1 staining ( Fig. 3c,f,i,j) and further indicates that basal numbers of NAc glutamatergic synapses were not affected by the Mecp2 308 mutation. Chronic AMPH treatment induced an increase in spine densities in WT mice relative to their vehicle controls ( Fig. 4) . By contrast, spine densities were not enhanced in AMPH-treated MUT mice compared with their vehicle controls, indicating a failure of this form of structural synaptic plasticity in the Mecp2 308/y MUT mice.
AMPH-inducible gene expression in Mecp2 mutant mice
To investigate the consequences of the Mecp2 mutation on regulation of gene expression programs, we quantified immediate early gene (IEG) expression in the NAc of Mecp2 +/y WT and Mecp2 308/y MUT mice after acute or repeated AMPH exposure ( Fig. 5) .
After acute injection, both genotypes showed similar levels of c-Fos expression in response to vehicle and to AMPH treatments ( Fig. 5a,b,e and Supplementary Fig. 3 ). By contrast, AMPH-treated levels of FosB were reduced by more than half in MUT compared to WT mice ( Fig. 5f,g,j) , whereas AMPH-treated levels of JunB were nearly twice as high in MUT mice ( Fig. 5h,i,k) . Chronic psychostimulant treatment has been shown to drive time-dependent changes in IEG inducibility 6, 28 . To assess whether this plasticity is altered by the Mecp2 308 mutation, we examined expression of c-Fos, FosB and JunB in WT or MUT mice that had been given repeated injections of vehicle or AMPH, withdrawn, and challenged with AMPH (see Supplementary Fig. 2) . As previously reported 6,28 , we found that repeated AMPH administration (AMPH:AMPH) of WT mice led to persistent desensitization of c-Fos and FosB induction ( Fig. 5a,c ,e,f,j) but increased JunB induction ( Fig. 5h,k ) compared to vehicle:AMPH treatment. By contrast, although these IEGs in MUT mice were induced by both single (Veh:AMPH) and multiple injections of AMPH (AMPH:AMPH), we observed no changes in the inducibility of any of these IEGs when comparing single to repeated administration of AMPH ( Fig. 5b,d ,e,j,k). Taken together, these data show that although NAc neurons in MUT mice were capable of mounting an IEG response to AMPH, both the magnitude and plasticity of this response were significantly altered.
Psychostimulant-induced phosphorylation of MeCP2
Transcriptional regulators that couple psychostimulant exposure to behavioral responses are targets of modulation by psychostimulantinduced intracellular signaling cascades 5 . Because phosphorylation of MeCP2 at Ser421 alters its ability to act as a transcriptional repressor 22 , we asked whether AMPH induces pMeCP2 in mesolimbocortical neurons. Adult male C57BL/6 mice received an acute injection of vehicle or 3 mg kg −1 AMPH, then were killed 0.5-24 h later and quantitative MeCP2 and pMeCP2 immunoreactivities assessed in coronal brain sections with antibodies specific to MeCP2 and phospho-Ser421 MeCP2 (ref. 22) ( Fig. 6) . MeCP2 was expressed in most neurons within the NAc, VTA and associated limbic structures ( Fig. 6b  and Supplementary Fig. 4 ). Vehicle-treated mice showed baseline levels of pMeCP2 immunoreactivities that varied among different brain regions ( Fig.6a and Supplementary Fig. 4 VOLUME 13 | NUMBER 9 | SEPTEMBER 2010 nature neurOSCIenCe a r t I C l e S neurons diffusely distributed throughout the shell and into the core of the NAc, without increasing overall expression of MeCP2 ( Fig. 6a-i) . AMPH induced pMeCP2 in a dose-dependent fashion, and pMeCP2 was induced also by administration of 10 mg kg −1 cocaine, another psychostimulant ( Fig. 6o) . AMPH and cocaine increase extracellular dopamine levels at the synapse, leading to activation of both D1-class (D1 and D5) and D2-class (D2, D3 and D4) receptors. To determine whether dopamine receptor signaling mediates the induction of pMeCP2 by psychostimulants, we injected mice first injected with vehicle or with 0.25 mg kg −1 SCH22390, a D1-class antagonist, followed 15 min later with 3 mg kg −1 AMPH. The antagonist significantly reduced the AMPH-induced expression of pMeCP2 in the NAc, suggesting that activation of D1-class receptors is required for this process (Fig. 6j,k,m,n) . When mice were given SKF81297, a D1-class receptor agonist, at doses that stimulate locomotor activity in the open field (data not shown), 5 mg kg −1 SKF81297 was sufficient to drive robust phosphorylation of MeCP2 in the NAc (Fig. 6j,l,n) . These data suggest that D1-class dopamine receptor signaling is both sufficient and necessary for AMPH-mediated induction of pMeCP2.
Of note, AMPH-induced pMeCP2 was largely restricted to the NAc, as we observed no significant increase of pMeCP2 in the caudate-putamen, VTA, basolateral amygdala or hippocampus after AMPH treatment (Supplementary Fig. 4) . There was an increase in pMeCP2 immunoreactivity in the prelimbic region of the frontal cortex 2 h after AMPH administration; however, baseline pMeCP2 levels in vehicle-treated mice were significantly elevated in prelimbic cortex compared with striatum (Fig. 6a,c and Supplementary Fig. 4) .
Neurons in the NAc comprise two main classes: more than 90% of the cells are MSNs, GABAergic projection neurons that carry efferent signals from the striatum; the remaining neurons are local interneurons that use GABA or acetylcholine as a neurotransmitter 29, 30 . To ascertain which neurons show changes in pMeCP2 levels after AMPH treatment, we first used BAC transgenic mouse lines that express fluorescent proteins in MSNs that express D1 or D2 receptors, respectively 31 . We were surprised to find no overlap in the NAc of the D1 or D2 receptor marker proteins with pMeCP2 in either of the mouse lines ( Fig. 7a,b) . Nevertheless, these mice showed a transcriptional response to AMPH in MSNs, as we could detect expression of c-Fos in a subset of fluorescent neurons in both lines of mice (Supplementary Fig. 5 ). By contrast, after AMPH treatment we observed extensive overlap with pMeCP2 in the Lhx6-GFP BAC transgenic line, which expresses green fluorescent protein (GFP) in a subset of GABAergic interneurons in striatum and cortex 32 (Fig. 7c  and Supplementary Fig. 6 ). Parvalbumin and glutamic acid decarboxylase (GAD)-67, two markers of fast-spiking GABAergic interneurons (FSIs) 30 , showed nearly complete colocalization with pMeCP2 in AMPH-treated mice (Fig. 7d,e ), suggesting that a large percentage of this population of GABAergic interneurons experience AMPH-induced MeCP2 phosphorylation. We saw no colocalization between pMeCP2 and somatostatin ( Fig. 7f) , which marks a different class of GABAergic interneurons, or between pMeCP2 and choline (j-k) Quantification of FosB and JunB expression. (j) In WT mice, FosB expression was reduced after repeated AMPH treatment (ANOVA; treatment-by-genotype, F 3,23 = 11.0, P = 0.003; *P < 0.001, Veh:AMPH WT compared to AMPH:AMPH WT). In MUT mice, the single injection of AMPH at challenge did not induce FosB expression as compared to that in WT mice (^P = 0.001, Veh:AMPH WT compared to Veh:AMPH MUT), and there was no difference between the Veh:AMPH MUT and AMPH:AMPH MUT groups (P = 0.96). (k) Repeated injection of AMPH upregulated JunB expression in WT mice (ANOVA; treatment-by-genotype, F 3,21 = 10.9, P = 0.004; *P = 0.01, Veh:AMPH WT compared to AMPH:AMPH WT). For MUT mice, acute AMPH injection at challenge significantly elevated JunB expression compared with that in similarly treated WT mice (^P < 0.001, Veh:AMPH WT compared to Veh:AMPH MUT); however, there was no statistical difference in JunB expression between the Veh:AMPH MUT and AMPH:AMPH MUT groups (P = 0.47). Error bars, mean ± s.e.m. (Fig. 7g) , a marker of cholinergic interneurons. Thus these data demonstrate a notable in vivo selectivity of psychostimulant-mediated induction of pMeCP2, preferentially in FSIs of the NAc.
pMeCP2 correlates with behavioral sensitization to AMPH To determine whether regulation of pMeCP2 changes after repeated exposure to psychostimulants, we quantified pMeCP2 in the NAc from mice that had been behaviorally sensitized to AMPH ( Fig. 8 and Supplementary Fig. 7a,b) . All groups that received AMPH on the challenge day (Veh:AMPH; AMPH:AMPH) showed induced pMeCP2 compared to the Veh:Veh and AMPH:Veh groups (Fig. 8c-g) , and the extent of induced pMeCP2 was largely confined to the NAc in both groups (data not shown). Mice that were given repeated injections of AMPH but received vehicle challenge (AMPH:Veh) showed no enhancement of pMeCP2 above Veh:Veh control levels (Fig. 8c,d,g) , suggesting that pMeCP2 is not persistently elevated by repeated AMPH treatment before AMPH challenge. However, a marked difference between the single AMPH (Veh:AMPH) and repeated AMPH (AMPH:AMPH) treatment groups emerged when a correlational analysis was applied to locomotor activity and NAc pMeCP2 expression in individual mice. No significant relationship between behavior and pMeCP2 induction was observed in individual mice that received a single injection of AMPH (Veh:AMPH) ( Fig. 8j and Supplementary Fig. 7c,d) or in either the Veh:Veh or AMPH:Veh groups (Fig. 8h,i) . By contrast, we observed a strong correlation of pMeCP2 expression with locomotion in the AMPH-treated mice given AMPH at challenge (AMPH:AMPH) ( Fig. 8k  and Supplementary Fig. 7e,f) . We found a similar correlation in the same mice between pMeCP2 and the expression of behavioral stereotypical activities (Supplementary Fig. 8) . These data indicate that for individual mice within the AMPH:AMPH group, the magnitude of pMeCP2 expression in the NAc predicted the degree of behavioral sensitization.
DISCUSSION
Using two different approaches, we found that changes in Mecp2 altered both AMPH-induced locomotion and the rewarding properties of this psychostimulant in CPP. First, using lentivirus to knock down or overexpress MeCP2 locally within the NAc, we found that levels of a r t I C l e S MeCP2 were inversely correlated with AMPH-induced locomotion and CPP. Of note, repeated cocaine administration is reported to drive an increase in MeCP2 expression in a subset of neurons in the dorsal caudate-putamen, frontal cortex and dentate gyrus 33 . Together with our experimental data, these observations raise the possibility that local alterations in MeCP2 expression within the mesolimbocortical dopamine circuit may act as a homeostatic compensatory mechanism to limit behavioral responses to AMPH. In our second approach, we found that hypomorphic Mecp2 308/y MUT mice had altered behavioral responses to both acute and repeated AMPH administration, further supporting a role for this transcriptional regulator in modulating behavioral responses to psychostimulants. Like the mice that underwent lentiviral-mediated knockdown, the Mecp2 308/y MUT mice showed enhanced locomotor responses to acute AMPH administration. However, unlike the virally infected mice, the Mecp2 308/y mutants did not show further enhanced locomotor activities after repeated AMPH injection, and they showed impaired CPP rather than the enhanced CPP we observed with lentivirus-mediated knockdown of Mecp2.
One explanation for differences we observe between requirements for MeCP2 in the adult NAc and the behavioral phenotypes in the Mecp2 308 mice is that some of the behavioral effects of the constitutive mutation may arise secondary to changes in mesolimbocortical circuit development. In this regard, we have shown that Mecp2 308/y MUT mice have twice as many NAc GABAergic synapses as their WT littermates. Null mutations in Mecp2 are associated with altered GABAergic synapse numbers in thalamic nuclei, although the mechanisms by which MeCP2 regulates GABAergic synapse development remain unknown 34 . Most inhibitory striatal synapses are of local origin: ~70% are from MSN collaterals, whereas the remainder arise from GABAergic interneurons 35 . MeCP2 is expressed in both types of neurons, and the magnitude of the increase in GABAergic synapses we detected is most consistent with the possibility that synapses in both populations of neurons are altered in Mecp2 308/y MUT mice. Although the specific behavioral consequences of changing GABAergic synapse connectivity within the NAc are unknown, chronic cocaine administration can increase the frequency of spontaneous inhibitory currents in D1 dopamine receptor-expressing neurons in striatal slices 36 .
However, beyond this evidence for altered NAc circuit development, we also found deficient neuronal plasticity in the NAc of adult Mecp2 308/y MUT mice after repeated AMPH administration. Changes in MSN dendritic spine density represent one cellular mechanism that may contribute to the development and/or expression of behavioral sensitization and CPP. Previous studies have demonstrated that repeated psychostimulant treatment induces an increase in the spine densities of MSNs in the NAc that persists for up to 1 month after drug withdrawal 2 , although whether this structural synaptic plasticity promotes 7,10 or limits 9,37 behavioral responses to psychostimulants remains unclear. We observed that spine densities were not increased by chronic AMPH treatment in Mecp2 308/y MUT mice. Furthermore, we found that these mice had deficient regulation of striatal IEG expression after repeated AMPH treatment. Acute treatment with cocaine or AMPH induces Fos, Fosb, Fosl2 and Junb transcription in the striatum 38 , whereas repeated psychostimulant exposure changes the inducibility of these IEGs over time through a process that is proposed to involve epigenetic mechanisms of chromatin regulation 6, 28, 39 . In the NAc of Mecp2 308/y MUT mice, acute AMPH-induced expression of FosB was impaired, whereas that of JunB was enhanced. Furthermore, these mice failed to show plasticity of IEG inducibility after repeated AMPH. The Fos and Jun family of transcription factors are functionally important transcriptional targets of psychostimulants [40] [41] [42] [43] . In particular, the Fosb splice variant ΔFosB lies near the pinnacle of a transcriptional cascade that increases dendritic spine densities in the NAc and sensitizes behavioral responses to psychostimulants 10 . Altered Fosb transcription in the Mecp 308/y mice could contribute to changes in spine densities and AMPH-induced behavior. However, the drug injection schedules for the CPP, spine density and gene expression protocols used here were not identical, so whether a r t I C l e S these biochemical and cellular deficiencies in the Mecp2 308/y mice are concurrent with the behavioral changes remains to be determined. Furthermore, although we observed no differences in spine densities between genotypes at baseline, the Mecp2 308/y MUT mice were much more sensitive to the locomotor-stimulating effects of psychostimulants than the Mecp2 +/y WT controls. Together, these data emphasize the challenges of linking single neural adaptations (for example, dendritic spine density) with the behavioral output of the mesolimbocortical dopamine circuit, and they raise the possibility that multiple cellular mechanisms may be capable of generating similar behavioral states.
We found that psychostimulants drove dopamine-dependent Ser421 phosphorylation of MeCP2 in brain, suggesting a mechanism through which these drugs may regulate MeCP2 function in close temporal association with the reception of rewarding stimuli. Pharmacological activation of D1-class dopamine receptors in vivo was required for the psychostimulant-dependent induction of pMeCP2 in a subset of GABAergic interneurons within the NAc. By contrast, these same stimuli did not induce pMeCP2 in striatal MSNs despite these neurons containing high levels of dopamine receptors. Because dopamine exerts systems-level effects on network excitability 29 and because MeCP2 phosphorylation is regulated by the activation of glutamate receptor-coupled intracellular calcium signaling cascades 22 , the most parsimonious interpretation of our data is that the selective pattern of MeCP2 phosphorylation after dopamine receptor activation in vivo is secondary to changes in neuronal firing.
Very little is known about the effects of chronic psychostimulant exposure on the firing properties or plasticity of striatal FSIs. Nonetheless it has been shown that dopamine excites FSIs in striatal slice preparations through pre-and postsynaptic mechanisms 44 . A recent study has shown that acute administration of AMPH increases the firing rate of FSIs in the striatum of freely moving rats in vivo 45 . Despite their small numbers, each FSI makes numerous inhibitory synapses onto the somata and proximal dendrites of multiple MSNs, such that cortical activation of a single FSI is sufficient to delay or block the generation of action potentials in a large number of MSNs 46, 47 . Phosphorylated MeCP2 may act in FSIs to acutely modulate their function, or, alternatively, changes in the extent of pMeCP2 after repeated AMPH exposure may reflect plasticity of the synaptic connections and intracellular signaling pathways that drive this phosphorylation event. In either case, our data suggest that future studies addressing a r t I C l e S dopamine-dependent plasticity and the role of pMeCP2 in FSIs of the NAc may lead to insights into behavioral responses to drugs of abuse.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureneuroscience/.
Note: Supplementary information is available on the Nature Neuroscience website.
immunostaining across treatment groups, we first spread sections from different individual mice into a Petri dish filled with PBS and photographed them with a high-resolution digital camera (Sony DSC-H1). We then mixed all sections for immunolabeling within a single chamber. We used the images collected before the staining to recover the identity of each section after staining. For immunolabeling, tissue sections were first permeabilized with either 1% (the pMeCP2 antibody) or 0.3% (all other experiments) Triton X-100 for 1 h at 25 °C, then blocked with 16% goat serum in PBS. We incubated sections with primary antibodies overnight at 4 °C. Whenever possible, we performed double immunostaining with primary antibodies raised in two species for colocalization on single sections. We applied species-specific fluorescent conjugated secondary antibodies for 1 h at 25 °C, and nuclei were labeled with Hoechst dye (Sigma) to facilitate anatomical localization of structures.
Image analyses. For quantitative immunofluorescence, we captured images on a Leica DMI4000 inverted fluorescence microscope using a Cascade 512B camera. We quantified digital images using MetaMorph 7 Image Analysis software (Molecular Devices). All images within one experiment were taken with a constant exposure time and aperture and were quantified using a single threshold value. We determined the threshold value as the average background immunofluorescence of vehicle control sections in each experiment. To reduce variation between mice, we counted pMeCP2 and total MeCP2 cell numbers and integrated intensity from a constant-sized region across the shell of the NAc. We used the Count Nuclei module in MetaMorph 7.0 to evaluate both cell numbers and integrated intensities of the pMeCP2 or MeCP2 immunoreactivities. Quantification of representative images from key experiments was independently verified by an investigator blind to the treatment conditions. For high-resolution colocalization, we captured images in a z-stack in MetaMorph 7.0 and subjected them to three-dimensional deconvolution processing using AutoQuant X2.1.1 software (Media Cybernetics, Inc.). For synaptic protein quantification, we captured three separate images from each section in z-stacks with a ×63 oil-immersion lens. After three-dimensional deconvolution processing, a four-consecutiveimage stack (equivalent to 2 μm thickness) was merged using the Average Stack Arithmetic module in MetaMorph 7.0. We then quantified the merged images using the Count Nuclei module in MetaMorph as described above. We eliminated the image farthest from the mean and averaged the remainder to obtain a value for each mouse.
Statistical analyses.
We performed all statistical analyses using SPSS v11.0 statistical software. The data are depicted as means and s.e.m. We analyzed comparisons of protein expression (for example, pMeCP2 or total MeCP2) or spine density data with one-way or two-way univariate analysis of variance (ANOVA) as necessary. We analyzed locomotor activity in the open field using multivariate repeated-measures ANOVA (RMANOVA) for activities at baseline and at 1 to 2 h after injection over 5-min intervals, using time as the withinsubjects effect, and genotype and treatment as the between-subjects effects.
In some experiments, we aggregated these data over 1 to 2 h after injection, as noted, and differences between treatments were analyzed with an independent-measures t-test. We analyzed CPP and sucrose preference test data within each genotype or treatment using RMANOVA, with preference scores as the within-subjects effect and treatment (for example, AMPH dose, sucrose and quinine concentration) as the between-subjects effect. In all cases, we conducted post-hoc analyses using Bonferroni-corrected pairwise comparisons. We assessed the correlation between pMeCP2 immunoreactivity and locomotor activity with Pearson correlation coefficients. In all cases, we considered P < 0.05 statistically significant. 
